Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2018

At a glance

  • Drugs Anti-CD38 CAR-T Cells-Sorrento Therapeutics (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Sorrento Therapeutics
  • Most Recent Events

    • 01 Nov 2018 According to the Sorrento Therapeutics media release, first patients were dosed at two clinical sites University of Pennsylvania (UPenn) in Philadelphia and Roger Williams Medical Center in Rhode Island.
    • 31 Aug 2018 Biomarkers information updated
    • 05 Apr 2018 According to the Sorrento Therapeutics media release, IND filing completed and company have started screening patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top